Biosimilar branded competitor assessment JAK inhibitor

Project Objective

Our client has a successful JAK inhibitor, “Product X”, which has large volumes of sales in the US; Product X sales are expected to continue to grow in the EU5, particularly through indication expansion
However, biosimilars and other JAK inhibitors represent key competitive threats for Product X, and our client was concerned of the impact of biosimilar price erosion on Product X’s price and access opportunity in the future
As such, the project objective was to assess the competitive threat to Product X from other branded and biosimilar agents, and develop risk mitigation strategies

We began by performing secondary research in 8 European markets across three market archetypes: physician driven, account driven, and markets with national tenders
We then identified scenarios for each archetype, including anticipated price evolution of biosimilars and pressure placed on Product X’s price through competitive behavior
For each scenario, we identified potential risks for Product X and key drivers of those risks
Finally, we facilitated an interactive, solution-oriented 3-day workshop with cross-functional teams
The workshop included simulating the prior erosion of adalimumab biosimilars by participants role playing biosimilar manufacturers and AbbVie

Windrose provided the following:
- Analysis of the competitive landscape including an assessment of how analogues can inform biosimilar price erosion and analysis of key strategies for biosimilar manufacturers
- Predictions for how the market will evolve in the future, including analysis of biosimilar procurement mechanisms and policies that may influence price erosion
- Risk Assessment Framework, to monitor real-time adalimumab biosimilars and associated P&MA impact to predict how competitors respond to biosimilar risk, the impact to the client and preparations to respond to risk
- Strategies to address competitors and actions for the client to maintain leadership versus other JAKs and biosimilars